TWI896517B - 雙專一性抗體及製造與使用其的方法 - Google Patents

雙專一性抗體及製造與使用其的方法

Info

Publication number
TWI896517B
TWI896517B TW107138958A TW107138958A TWI896517B TW I896517 B TWI896517 B TW I896517B TW 107138958 A TW107138958 A TW 107138958A TW 107138958 A TW107138958 A TW 107138958A TW I896517 B TWI896517 B TW I896517B
Authority
TW
Taiwan
Prior art keywords
seq
cancer
bispecific antibody
antibody
binding specificity
Prior art date
Application number
TW107138958A
Other languages
English (en)
Chinese (zh)
Other versions
TW201927819A (zh
Inventor
朱義
卡特里娜 貝科娃
迪比爾 布雷
布萊爾 倫肖
冬 夏
澤人 高
布萊恩 科瓦切維奇
喬納森Ｋ 法倫
菲爾 譚
Original Assignee
美商西雅圖免疫公司
大陸商四川百利藥業有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西雅圖免疫公司, 大陸商四川百利藥業有限責任公司 filed Critical 美商西雅圖免疫公司
Publication of TW201927819A publication Critical patent/TW201927819A/zh
Application granted granted Critical
Publication of TWI896517B publication Critical patent/TWI896517B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW107138958A 2017-11-02 2018-11-02 雙專一性抗體及製造與使用其的方法 TWI896517B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580845P 2017-11-02 2017-11-02
US62/580,845 2017-11-02

Publications (2)

Publication Number Publication Date
TW201927819A TW201927819A (zh) 2019-07-16
TWI896517B true TWI896517B (zh) 2025-09-11

Family

ID=66332369

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107138958A TWI896517B (zh) 2017-11-02 2018-11-02 雙專一性抗體及製造與使用其的方法

Country Status (11)

Country Link
US (1) US20200347137A1 (enExample)
EP (1) EP3703736A4 (enExample)
JP (1) JP7418326B2 (enExample)
KR (2) KR102785809B1 (enExample)
CN (2) CN117343193A (enExample)
AU (1) AU2018358138C1 (enExample)
CA (1) CA3069238A1 (enExample)
IL (1) IL271346A (enExample)
SG (1) SG11202003237QA (enExample)
TW (1) TWI896517B (enExample)
WO (1) WO2019090002A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン， インク． 抗ｐｄ－ｌ１抗体とその作製及び使用方法
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
EP4061849A4 (en) * 2019-11-21 2024-05-29 Brown University BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
EP4069746A4 (en) * 2019-12-04 2023-12-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
TW202511295A (zh) * 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途
CN122161858A (zh) * 2023-09-18 2026-06-05 翰思艾泰生物医药科技(武汉)股份有限公司 靶向ctla4和cd47的抗体及其用途
WO2026061422A1 (en) * 2024-09-18 2026-03-26 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN106967172A (zh) * 2016-08-23 2017-07-21 中山康方生物医药有限公司 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496134T1 (de) * 2002-03-29 2011-02-15 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
AU2006230413B8 (en) * 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP3683314A1 (en) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN106967172A (zh) * 2016-08-23 2017-07-21 中山康方生物医药有限公司 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
SG11202003237QA (en) 2020-05-28
TW201927819A (zh) 2019-07-16
US20200347137A1 (en) 2020-11-05
JP2021501575A (ja) 2021-01-21
RU2020108444A3 (enExample) 2022-03-17
CN111212658B (zh) 2024-05-03
AU2018358138A1 (en) 2020-04-23
EP3703736A4 (en) 2021-11-03
CA3069238A1 (en) 2019-05-09
NZ763370A (en) 2024-10-25
CN111212658A (zh) 2020-05-29
CN117343193A (zh) 2024-01-05
IL271346A (en) 2020-01-30
KR20250044943A (ko) 2025-04-01
KR20200091382A (ko) 2020-07-30
EP3703736A1 (en) 2020-09-09
KR102785809B1 (ko) 2025-03-26
AU2018358138B2 (en) 2022-06-02
JP7418326B2 (ja) 2024-01-19
AU2018358138C1 (en) 2022-12-08
WO2019090002A1 (en) 2019-05-09
RU2020108444A (ru) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7082574B2 (ja) 免疫療法用改変細胞
CN109563165B (zh) 抗ctla-4抗体
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
CN107428832B (zh) 抗pd-l1抗体
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
CA3175140A1 (en) Novel anti-lilrb4 antibodies and derivative products
JP2019517773A (ja) 抗ｌａｇ−３抗体
CN110167966A (zh) 程序性细胞死亡(pd-1)的单结构域抗体
CN112955469B (zh) 新型拮抗性抗tnfr2抗体分子
CN110799540A (zh) 多特异性抗体及其制备和使用方法
AU2015329965A1 (en) Bispecific antibodies against CD3epsilon and ROR1
CN117222672A (zh) 抗cldn4-抗cd137双特异性抗体
US12221480B2 (en) Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof
WO2015172341A1 (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
CN116635071A (zh) 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
US20260085127A1 (en) Bispecific antibody to human tim-3 and human cd39, and use thereof
US20230265185A1 (en) Anti-cd22 single domain antibodies and therapeutic constructs
HK40097105A (en) Bispecific antibodies and methods of making and using thereof
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40090244A (en) Multispecific antibodies that bind both mait and tumor cells
HK40109442A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40010370A (en) Tri-chain antibody, preparation method and use thereof
HK40050308B (en) Novel antagonistic anti tnfr2 antibody molecules